Physician profile
Toby Levenson
NPI 1649288945
$6,278.48
in general payments reported to CMS, 2019-2025
21 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $579 · 2021: $808 · 2022: $1,037 · 2023: $1,039 · 2024: $1,174 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Education: $23.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.94 |
| Education | $23.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,649.64 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,634.89 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $529.97 | 2020-2023 | |
| Genzyme Corporation | $473.61 | 2019-2025 | |
| Mylan Specialty L.P. | $358.46 | 2022-2024 | Yupelri |
| Pfizer INC. | $318.27 | 2019-2024 | |
| Amgen INC. | $315.67 | 2022-2025 | Tezspire |
| Optinose US, INC. | $154.55 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.85 | 2021-2024 | Cuvitru |
| Genentech USA, INC. | $101.30 | 2024-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $97.53 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $88.63 | 2019-2024 | Dupixent |
| Bio Products Laboratory USA, INC. | $78.17 | 2022-2023 | Coagadex, Gammaplex |
| Grifols USA, LLC | $75.23 | 2024-2025 | Xembify |
| Viatris Specialty LLC | $73.82 | 2025 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $65.03 | 2022 | |
| Hospira, INC. | $49.25 | 2023-2024 | |
| Octapharma USA, INC. | $41.09 | 2025 | Cutaquig |
| Merck Sharp & Dohme LLC | $23.77 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.02 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $13.73 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Levenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.